GlassScriptPhysician profile
Ameer Abutaleb
NPI 1639598444
$2,520.18
in general payments reported to CMS, 2019-2025
20 companies · $642 in 2025
The $642 reported for 2025 was less than what a typical Hepatology provider received nationally (typical 2025 total: $981).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $21.56 · 2020: $21.36 · 2022: $403 · 2023: $622 · 2024: $810 · 2025: $642.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,074.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,074.16 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $602.26 | 2022-2024 | Therasphere Y90 Glass Microspheres 10 Gbq |
| Mallinckrodt Hospital Products INC. | $270.46 | 2022-2024 | Terlivaz, Acthar |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $242.64 | 2023-2025 | Xifaxan |
| Dilon Technologies, INC. | $201.74 | 2025 | Hemoblast Bellows |
| Veloxis Pharmaceuticals, INC. | $189.20 | 2022-2024 | Envarsus |
| Madrigal Pharmaceuticals | $176.95 | 2024-2025 | Rezdiffra, Resmetirom |
| Abbvie INC. | $174.70 | 2023-2025 | Mavyret |
| Gilead Sciences, INC. | $170.56 | 2023-2025 | Epclusa |
| Shionogi INC | $128.54 | 2019-2025 | Fetroja |
| Takeda Pharmaceuticals U.S.A., INC. | $62.66 | 2022-2024 | Livtencity |
| Alexion Pharmaceuticals, INC. | $59.16 | 2023-2024 | Ultomiris, Soliris |
| Intercept Pharmaceuticals, INC. | $41.33 | 2020-2024 | |
| Melinta Therapeutics, LLC | $31.55 | 2024 | Rezzayo, Vabomere |
| Astellas Pharma US INC | $30.40 | 2025 | Cresemba |
| Ethicon US, LLC | $28.22 | 2025 | Prolene, Surgicel Nu-Knit, Evarrest |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Baxter Healthcare | $28.20 | 2023 | Floseal |
| Ipsen Biopharmaceuticals, INC | $25.06 | 2025 | Iqirvo |
| Novo Nordisk INC | $18.94 | 2025 | Wegovy |
| Merck Sharp & Dohme LLC | $18.82 | 2025 | Prevymis |
| Exact Sciences Corporation | $18.79 | 2023 | Cologuard Collection Kit |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ameer Abutaleb listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.